- Home
- DGHI vs OVID Comparison
DGHI vs OVID Comparison
Compare DGHI & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGHI
- OVID
- Stock Information
- Founded
- DGHI 2017
- OVID 2014
- Country
- DGHI United States
- OVID United States
- Employees
- DGHI N/A
- OVID N/A
- Industry
- DGHI Finance: Consumer Services
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- DGHI Finance
- OVID Health Care
- Exchange
- DGHI Nasdaq
- OVID Nasdaq
- Market Cap
- DGHI 61.7M
- OVID 73.1M
- IPO Year
- DGHI N/A
- OVID 2017
- Fundamental
- Price
- DGHI $2.10
- OVID $1.02
- Analyst Decision
- DGHI Strong Buy
- OVID Strong Buy
- Analyst Count
- DGHI 1
- OVID 5
- Target Price
- DGHI $2.50
- OVID $4.04
- AVG Volume (30 Days)
- DGHI 263.9K
- OVID 210.4K
- Earning Date
- DGHI 11-15-2024
- OVID 11-12-2024
- Dividend Yield
- DGHI N/A
- OVID N/A
- EPS Growth
- DGHI N/A
- OVID N/A
- EPS
- DGHI N/A
- OVID N/A
- Revenue
- DGHI $42,146,057.00
- OVID $631,695.00
- Revenue This Year
- DGHI N/A
- OVID $71.38
- Revenue Next Year
- DGHI N/A
- OVID $5,144.81
- P/E Ratio
- DGHI N/A
- OVID N/A
- Revenue Growth
- DGHI 100.56
- OVID 113.21
- 52 Week Low
- DGHI $0.84
- OVID $0.68
- 52 Week High
- DGHI $2.54
- OVID $4.10
- Technical
- Relative Strength Index (RSI)
- DGHI 53.99
- OVID 44.47
- Support Level
- DGHI $1.56
- OVID $1.00
- Resistance Level
- DGHI $2.22
- OVID $1.09
- Average True Range (ATR)
- DGHI 0.23
- OVID 0.08
- MACD
- DGHI -0.02
- OVID -0.00
- Stochastic Oscillator
- DGHI 60.61
- OVID 27.27
About DGHI Digihost Technology Inc. Common Subordinate Voting Shares
Digihost Technology Inc is a blockchain company focused on Bitcoin mining. The company's mining facility is located in Buffalo, New York, and is equipped with an 18.7 MVA 115,000-kilovolt ampere outdoor substation with an option to increase the power output to 42MVA.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.